← GLP-1 receptor agonists × glycemic control

TrialThe lancet. Diabetes & endocrinology2014

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Stephen C L Gough et al.PubMed ↗Publisher ↗

The primary results report of NCT01336023. Its numbers are set against the trial’s posted results below.

What the trial testedas reported · 1,663 people · 2014

Not counted

Lowered glycemic control

−0.47percentage points−0.58 to −0.36

As reported

difference −0.47 %, 95% CI −0.58 to −0.36

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −0.47 (−0.58 to −0.36)Posted, primary outcome difference −0.47 (−0.58 to −0.36)Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.

One number in the abstract

the abstract, start to end

… degludec (estimated treatment difference -0.47%, 95% CI -0.58 to -0.36, …

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.47−0.58 to −0.36
GLP-1 receptor agonistsInsulinGlycemic control
1 / 3

174 papers cite itlatest 60 shown

2014
…
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01336023phase 31,663 enrolled2011this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 25190523